QPS completes acquisition of Xendo

Friday, July 30, 2010 08:14 AM

QPS Holdings, a CRO providing testing services to support preclinical and clinical research and development, announced the completion of its acquisition of Xendo Drug Development (XDD), headquartered in Groningen, The Netherlands.

XDD, a European CRO, will be known as QPS Netherlands BV and become a wholly-owned subsidiary of QPS Holdings, LLC. XDD has large and small molecule bioanalytical laboratories and a dedicated 24-bed clinical pharmacology unit (CPU) located at University Medical Center Groningen (UMCG). Established in 2004, this CPU has performed more than 100 clinical pharmacology studies across all major therapeutic areas. This location provides comprehensive safety monitoring with 24/7 access to hospital-based crash teams and clinical specialists.

XDD also offers an extensive database of healthy volunteers as well as special and patient populations. "Pooling our strengths will enable XDD and QPS to serve our clients even better. Our leading capability in conducting high quality bioanalysis and phase I studies, combined with our well established expertise in ADME, genotyping and drug development process will make QPS an ideal drug development partner for our pharmaceutical and biotech clients worldwide," said Ben Chien, chairman, and CEO of QPS Holdings.

Koos Koops, XDD's former CEO, added, “Joining the QPS organization enables XDD to realize its ambitions for global growth. In terms of activities, size and location, QPS and XDD are a perfect fit. Our combined operations in Asia, Europe and the US position us ideally to expand our portfolios in the increasingly consolidated pharmaceutical and biotechnology sector, our primary market." Koops will head the XDD -QPS Netherlands division of QPS.

Established in 1999, XDD employs more than 100 people, and provides early and late phase clinical development, data management, biometrics, medical writing, bioanalysis and resourcing solutions services. Founded in 1995, QPS has bioanalysis and DMPK facilities at its Newark, Del. headquarters, a laboratory in Taipei, Taiwan, and phase I facility in Missouri.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs